tetano
Editor, Senior Moderator
Biol Pharm Bull. 2017;40(7):954-959. doi: 10.1248/bpb.b16-00774.
[h=1]Pinanamine Is a Promising Lead Compound against Influenza A Virus: Evidence from in Vitro and in Vivo Efficacy Compared to Amantadine.[/h] Li R[SUP]1[/SUP], Yang C[SUP]1[/SUP], Du Q[SUP]1[/SUP], Zhao X[SUP]2[/SUP], Jiang H[SUP]1[/SUP], Hu W[SUP]1,[/SUP][SUP]2[/SUP], Yang Z[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses with the presence of mutations in M2 still circulate and threaten to avian species and human in China. A novel M2 inhibitor pinanamine was previously identified as an antiviral agent by an in vitro assay. In this study, we monitored the activity of pinanamine against influenza A/FM1/47 (H1N1) virus infection in cell culture and mice. Pinanamine showed more potent antiviral effect than ribavirin, and was as effective as oseltamivir carboxylate and amantadine in Madin-Darby canine kidney (MDCK) cells. Pinanamine at dose of 50 mg/kg/d administrated once a day for 6 d starting 24 h prior to virus exposure promoted survival rate of infected mice to 100% (p<0.001) and produced significant reduction (p<0.001) in lung virus yields and lung index. Even lower the dose of 3.1 mg/kg/d, pinanamine was 60% protective (p<0.05), which was equivalent to treatment with amantadine at 50 mg/kg/d. Our finding highlights the potential of pinanamine as a promising lead compound for influenza A virus.
[h=4]KEYWORDS:[/h] M2 inhibitor; in vitro; in vivo; influenza A virus; pinanamine
PMID: 28674259 DOI: 10.1248/bpb.b16-00774
Free full text
[h=1]Pinanamine Is a Promising Lead Compound against Influenza A Virus: Evidence from in Vitro and in Vivo Efficacy Compared to Amantadine.[/h] Li R[SUP]1[/SUP], Yang C[SUP]1[/SUP], Du Q[SUP]1[/SUP], Zhao X[SUP]2[/SUP], Jiang H[SUP]1[/SUP], Hu W[SUP]1,[/SUP][SUP]2[/SUP], Yang Z[SUP]1,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A viruses with the presence of mutations in M2 still circulate and threaten to avian species and human in China. A novel M2 inhibitor pinanamine was previously identified as an antiviral agent by an in vitro assay. In this study, we monitored the activity of pinanamine against influenza A/FM1/47 (H1N1) virus infection in cell culture and mice. Pinanamine showed more potent antiviral effect than ribavirin, and was as effective as oseltamivir carboxylate and amantadine in Madin-Darby canine kidney (MDCK) cells. Pinanamine at dose of 50 mg/kg/d administrated once a day for 6 d starting 24 h prior to virus exposure promoted survival rate of infected mice to 100% (p<0.001) and produced significant reduction (p<0.001) in lung virus yields and lung index. Even lower the dose of 3.1 mg/kg/d, pinanamine was 60% protective (p<0.05), which was equivalent to treatment with amantadine at 50 mg/kg/d. Our finding highlights the potential of pinanamine as a promising lead compound for influenza A virus.
[h=4]KEYWORDS:[/h] M2 inhibitor; in vitro; in vivo; influenza A virus; pinanamine
PMID: 28674259 DOI: 10.1248/bpb.b16-00774
Free full text